Search results
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks via Yahoo Finance· 3 days agoArexvy generated sales worth £182 million in the first quarter of 2024. PFE’s Abrysvo also witnessed...
There's a new highly transmissible COVID-19 variant. Could FLiRT lead to a summer uptick?
LA Times via Yahoo News· 6 days agoIn years past, summer travel and gatherings have spurred surges in coronavirus infections. As...
There's a new highly transmissible COVID-19 variant. Could FLiRT lead to a summer uptick?
Los Angeles Times· 6 days agoTwo new COVID-19 subvariants, collectively nicknamed FLiRT, are increasingly edging out the winter’s...
Novavax Starts A New Chapter, Turning The Page On Financial Uncertainty
RTT News· 4 days agos (NVAX) future as a going concern seemed uncertain, a remarkable turnaround has unfolded, thanks to the license deal with Sanofi (SNY). The deal signed with Sanofi on May 10, 2024, relates ...
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
Pharmaceutical Technology via Yahoo Finance· 2 days agoCircRNA is still in very early days of development, but it is expected to trialled in vaccines,...
Moderna's RSV Vaccine Approval Faces Setback as FDA Delays Decision
Homenewshere.com· 6 days agoModerna announced that the FDA had delayed approval of its RSV vaccine to the end of May due to...
There's a new highly transmissible COVID-19 variant: Could FLiRT lead to a summer uptick?
Medical Xpress· 3 days agoTwo new COVID-19 subvariants, collectively nicknamed FLiRT, are increasingly edging out the winter's...
UF Health scientists make breakthrough in possible cancer treatment
The Gainesville Sun· 2 days agoThe vaccine uses mRNA (messenger RNA) technology and lipid nanoparticles, which a news release said...
2 Top Growth Stocks Down 24% and 50% to Buy With $100
Motley Fool via Yahoo Finance· 10 hours agoShares are trading for a mere $28 apiece right now, down 24% from one year ago. On the one hand,...
Does Medicare Cover the RSV Vaccine?
US News Health· 2 days agoCDC recommends vaccination for higher-risk populations. Two vaccines – Arexvy and Abrysvo – are currently approved by the FDA for those ages 60 and older ...